Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) fell 10.3% during trading on Tuesday . The stock traded as low as $1.55 and last traded at $1.66. 120,820 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 267,068 shares. The stock had previously closed at $1.85.

Nautilus Biotechnology Trading Down 10.3 %

The firm has a market capitalization of $207.04 million, a P/E ratio of -3.39 and a beta of 0.84. The company's fifty day simple moving average is $1.90 and its 200 day simple moving average is $2.29.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in shares of Nautilus Biotechnology by 11.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 123,683 shares of the company's stock worth $263,000 after buying an additional 12,705 shares during the period. State Street Corp grew its position in shares of Nautilus Biotechnology by 12.4% in the 3rd quarter. State Street Corp now owns 652,325 shares of the company's stock worth $1,383,000 after buying an additional 72,142 shares during the period. Prelude Capital Management LLC purchased a new stake in shares of Nautilus Biotechnology in the 3rd quarter worth about $37,000. Citadel Advisors LLC grew its position in shares of Nautilus Biotechnology by 82.0% in the 3rd quarter. Citadel Advisors LLC now owns 63,062 shares of the company's stock worth $134,000 after buying an additional 28,412 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Nautilus Biotechnology by 40.1% in the 3rd quarter. Renaissance Technologies LLC now owns 89,100 shares of the company's stock worth $189,000 after buying an additional 25,500 shares during the period. 45.25% of the stock is owned by hedge funds and other institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

See Also

• Get a free copy of the StockNews.com research report on Nautilus Biotechnology (NAUT)
• 3 Industrial Stocks to Help Build Your 2023 Watchlist
• The Institutions Choose CarMax Over Carvana, Should You?
• Heatmap in Trading: How to Learn What Market Depth Hides
• Micron Technology Sees Chip Recovery by the End of 2023
• Three Healthcare Penny Stocks to Watch In The New Year

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.